EP2374466B1 - Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire - Google Patents

Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire Download PDF

Info

Publication number
EP2374466B1
EP2374466B1 EP11169342.0A EP11169342A EP2374466B1 EP 2374466 B1 EP2374466 B1 EP 2374466B1 EP 11169342 A EP11169342 A EP 11169342A EP 2374466 B1 EP2374466 B1 EP 2374466B1
Authority
EP
European Patent Office
Prior art keywords
seq
protein
aureus
staphylococcus aureus
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11169342.0A
Other languages
German (de)
English (en)
Other versions
EP2374466A1 (fr
Inventor
Martin Prof. Dr. Krönke
Oleg Krut
Eva Glowalla
Bettina Tosetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kronke Martin
Original Assignee
Kronke Martin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kronke Martin filed Critical Kronke Martin
Priority to EP11169342.0A priority Critical patent/EP2374466B1/fr
Publication of EP2374466A1 publication Critical patent/EP2374466A1/fr
Application granted granted Critical
Publication of EP2374466B1 publication Critical patent/EP2374466B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Definitions

  • the present invention relates to a pharmaceutical composition or a medicament, notably a protective Staphylococcus aureus vaccine, comprising at least one cell wall-associated Staphylococcus aureus protein being the triosephosphate isomerase of SEQ ID NO:38 or a fragment or derivative thereof causing an immune response that induces opsonophagocytic activity of human neutrophils for S . aureus.
  • a protective Staphylococcus aureus vaccine comprising at least one cell wall-associated Staphylococcus aureus protein being the triosephosphate isomerase of SEQ ID NO:38 or a fragment or derivative thereof causing an immune response that induces opsonophagocytic activity of human neutrophils for S . aureus.
  • Staphylococcus aureus is a nosocomial as well as a community-acquired pathogen, which causes several diseases, ranging from minor skin infections to serious life-threatening wound infections, bacteraemia, endocarditis, pneumonia and toxic shock syndrome ( Lowy F. D., N. Engl. J. Med., 339(8):520-32 (1998 )).
  • the worldwide growing incidence of staphylococcal infections is strongly related to the increased use of surgical devices and a growing number of immunocompromised patients. The situation has become more serious, since the increased use of antibiotics led to the emergence of methicillin-resistant S . aureus strains (MRSA) ( Selvey L. A. et al., Infect. Control. Hosp.
  • Vaccination with capsular polysaccharides demonstrated reduced severity of staphylococcal infections in animals and humans ( Fattom A. et al., Vaccine, 23(5):656-63 (2004 ); Fattom A. I. et al., Infect. Immun., 64(5): 1659-65 (1996 )). Since vaccines based on capsular polysaccharides induce only serotype-specific protection, a bivalent vaccine against S . aureus serotype 5 and 8 was developed, which comprises about 75% of the most infectious strains. Due to the poor immunogenicity of polysaccharides, conjugation to a carrier protein was required to induce humoral immune responses.
  • the CP vaccine elicited high antibody levels in dialysis patients, though not leading to a significant long term protection against bacteraemia ( Fattom A. I. et al., Vaccine, 22(7):880-7 (2004 )).
  • immunisation with known staphylococcal virulence factors provided a protective immune response against S . aureus in animal models.
  • a specific humoral response raised against single extracellular matrix binding proteins like clumping factor A (ClfA), fibronectin-binding protein (FnBP) or collagen-binding protein (Cna) conferred a reduced susceptibility to staphylococcal colonisation ( Mamo W. et al., Microbiol.
  • IVIG preparations are successfully used in the treatment of patients with antibody deficiencies, in order to reduce their high susceptibility to bacterial infections ( Lamari F. et al., J. Pharm. Biomed. Anal., 22(6):1029-36 (2000 )). Since such preparations consist of purified IgGs derived from not less than thousand plasma donors, they are characterised by a broad spectrum of opsonising antibodies against various pathogens including S . aureus. The administration of antibodies against bacterial surface antigens provides opsonisation, complement activation and the phagocytosis of the bacteria ( Lamari F. et al., J. Pharm. Biomed. Anal., 22(6):1029-36 (2000 ); Ono Y. et al., J.
  • IVIG antibody source intravenous immunoglobulin preparations
  • S . aureus a broad spectrum of opsonising antibodies against various pathogens including S . aureus.
  • 2-DE gel electrophoresis subtractive immunoblotting and mass spectrometry several cell wall-associated proteins were identified as novel potential vaccine protein targets.
  • SUPRA su subtractive pr oteome a nalysis
  • the protective activity of antibodies raised against some of the identified proteins was demonstrated in vitro and in a murine sepsis model. The invention thus provides
  • IVIG intravenous immunoglobulin preparation
  • Affinity purified anti-Eno, anti-Oxo and anti hp2160 antibodies showed significant opsonising activity enabling uptake and killing of S . aureus by human neutrophils.
  • Significant antibody responses were elicited in mice immunised with recombinant antigens.
  • S . aureus reduced staphylococcal spread was detected in immunised mice by in vivo imaging system.
  • the recovery of S . aureus CFUs from organs of immunised mice was diminished by 10-100-fold.
  • the results of this study suggest our approach to be a valuable tool for the identification of novel vaccine candidates and therapeutic antibodies.
  • each of these S . aureus proteins proved to be able to induce an efficient immune response, establishing protective immunity to S . aureus.
  • the cell wall-associated protein is preferably derived from S . aureus strain ATCC 29213 (American type culture collection) (commercially available at ATCC, Manassas, VA (USA)).
  • the cell wall associated protein solely reacts with an intravenous immunoglobulin (iVIG) preparation but not with an iVIG preparation depleted of S. aureus-specific opsonising antibodies.
  • iVIG intravenous immunoglobulin
  • fragments within the meaning of the invention comprises a continuous segment out of the above proteins having at least 5 amino acid residues, preferably at least 10 amino acid residues.
  • deletion within the meaning of the invention comprises deletion, substitution and addition muteins of the above proteins and combinations thereof.
  • a deletion mutein lacks up to 10, preferably up to 5 continuous or separate amino acid residues, relative to the starting protein sequence.
  • a substitution mutein has substituted up to 10, preferably up to 5 continuous or separate amino acid residues, relative to the starting protein sequence.
  • An addition mutein has added up to 10, preferably up to 5 continuous or separate amino acid residues, relative to the starting protein sequence.
  • derivative also covers chemical modifications of the protein (e.g.
  • composition or medicament as defined in (1) to (6) above may further comprise pharmaceutically acceptable carriers (as well as pharmaceutically acceptable binders, stabilizers or excipients) which are required for the administration of the pharmaceutical composition or medicament to the human or animal patients.
  • the proteome analysis revealed nearly 40 cell wall-associated vaccine candidates, which were specifically recognised by opsonising IgGs.
  • a number of the identified proteins are already known as staphylococcal virulence factors, like the fibrinogenbinding, bone sialoprotein-binding protein ( Yacoub A. et al., Eur. J. Biochem., 222(3):919-25 (1994 )), ⁇ -hemolysin ( Hedstrom S. A. et al., Acta. Pathol. Microbiol. Immunol. Scand. [B], 90(3):217-20 (1982 )) or enterotoxin M (SEM) ( Jarraud S. et al., J.
  • IsaA and EF-Tu are proteins, already identified by serological proteome analysis (SERPA) ( Vytvytska O.
  • enolase Eno
  • Oxo oxoacyl-reductase
  • hp2160 the hypothetical protein
  • Enolase was shown to be located on the cell surface of S . aureus and to bind extracellular matrix components like laminin ( Carneiro C. R. et al., Microbes. Infect., 6(6):604-8 (2004 )) and plasminogen ( Molkanen T. et al., FEBS Lett., 517(1-3):72-8 (2002 )); its important role as staphylococcal virulence factor seems indisputable. Immunisation with recombinant enolase successfully reduced staphylococcal colonisation of S . aureus. The protective activity of enolase seems to be not limited to S . aureus.
  • Oxo displays characteristics of enzymes, involved in fatty acid biosynthesis and the hp2160 sequence shows similarity to esterase, an enzyme with lipolytic activity.
  • aureus pathogenesis are anchored to the bacterial cell wall by a transpeptidation mechanism that requires the C-terminal sorting signal with a conserved LPXTG motif ( Navarre W. W. et al., Microbiol. Mol. Biol. Rev., 63(1):174-229 (1999 )). Indeed, mice immunised with a combination of four such antigens, previously tested for their distinct immunogenic properties, were protected against lethal challenge with clinical S . aureus isolates. However, numerous novel, anchorless proteins with adhesive and invasive properties that do not contain either a signal peptide or the LPXTG motif were identified in the past few years. The mechanism, by which these proteins are secreted and reassociated with the surface is still unknown ( Chhatwal G. S.
  • Tpn a protein exhibiting GAPDH activity and called Tpn was identified on the staphylococcal surface. Tpn was demonstrated to possess transferrin-binding activity ( Modun B. et al., Infect. Immun., 67(3):1086-92 (1999 )).
  • Another anchorless, broad-spectrum adhesin Eap Hansen U. et al., Matrix Biol., 25(4):252-60 (2006 ); Palma M. et al., J.
  • Bacteriol., 181(9):2840-5 (1999 )) binds to a large variety of host components, recognising not only fibronectin, fibrinogen or prothrombin, but also collagens, laminin and other extracellular matrix proteins ( Palma M. et al., J. Bacteriol., 181(9):2840-5 (1999 ); McGavin M. H. et al., Infect. Immun., 61(6):2479-85 (1993 )). Each of these anchorless proteins was shown to play an important role in the pathogenesis of S . aureus, which underscores the continued necessity to search for vaccine candidates lacking the LPXTG motif.
  • antibodies against the protein of SEQ ID NO:38 above are also disclosed.
  • Such antibodies which may be employed in the pharmaceutical composition or medicament of (5) above or the medicament of (6) above, can be prepared (i.e. raised against the antigen) by suitable methods known to a skilled person.
  • S. aureus strain ATCC 29213 was obtained from the American Type Culture Collection (ATCC) and was used for the extraction of cell wall-associated proteins.
  • ATCC American Type Culture Collection
  • GFP-expressing S. aureus ATCC 29213
  • the bioluminescent S . aureus Xen29 applied for in vivo imaging studies, was purchased from Xenogen Corp. (Alameda, USA). This strain was derived from the virulent S.
  • aureus ATCC 12600 strain is characterised by its possibility to synthesise the luciferase enzyme as well as its substrate constitutively ( Francis K. P. et al., Infect. Immun., 68(6):3594-600 (2000 ); Kadurugamuwa J. L. et al., Infect. Immun., 71(2):882-90 (2003 )).
  • Escherichia coli strains Top 10, DH5 ⁇ and BL21 (Invitrogen Corp., Düsseldorf, Germany) were used.
  • S. aureus ATCC 29213 from agar plate was precultured in Luria-Bertani (LB) broth at 37°C with constant shaking to log growth. An aliquot of the preculture was inoculated into 200 ml of LB broth to obtain a starting optical density (OD 600 ) of 0.05.
  • the bacteria were cultured with constant shaking at 37°C under aerobic conditions until early exponential growth phase was reached. Bacteria were pelleted by centrifugation at 17,000 x g for 20 min at 4°C and the pellets washed twice in 10 mM TE-buffer, pH 8.0.
  • the cell wall-associated proteins were extracted according to the method of Antelmann ( Antelmann H.
  • the precipitate was collected by centrifugation at 17,000 x g for 60 min, and 4°C, washed three times with ice-cold ethanol and dried under vacuum. Extracted proteins were dissolved in 8M urea for two-dimensional gel electrophoresis (2-DE). The protein concentration was determined using the Bio-Rad DC protein assay kit (Bio-Rad, Germany) according to the instructions of the manufacturer.
  • Subtractive proteome analysis 2-DE was performed according to the method described by Bernardo et al. ( Bernardo K. et al., Antimicrob. Agents Chemother., 48(2):546-444 (2004 )) using the Multiphor II (Pharmacia-FRG) system according to the instructions of the manufacturer. Proteins dissolved in 8 M urea were separated on 18 cm immobilised pH gradient (IPG) strips in a nonlinear pH range of 3-10 and 4-7 (GE Healthcare, Munich, Germany). Isoelectric focusing (IEF) was performed using 500 ⁇ g protein for coomassie and 100 ⁇ g for silver gels and western blots.
  • IPG immobilised pH gradient
  • Proteins were solubilised in rehydration buffer (8 M urea, 2 M thiourea, 40 mM DTT, 1% CHAPS, 0.5% Pharmalyte and separated according to their pIs (isoelectric point) using the Multiphor II. After IEF, rod gels were equilibrated first in equilibration buffer (50 mM Tris-HCL [pH 8.8], 8 M urea, 2 M thiourea, 30% glycerol, 2% SDS, 0.05% bromophenol blue) containing 3.5 mg/ml DTT, followed by equilibration in equilibration buffer containing 45 mg/ml iodoacetamide and applied to SDS-PAGE. The proteins were separated on 12.5% Tris-glycine SDS gels (25 cm, 20 cm, 1.0 mm) using the Ettan Dalt II system (GE Healthcare).
  • equilibration buffer 50 mM Tris-HCL [pH 8.8], 8 M
  • Immunoblotting Proteins separated by 2-DE were transferred to nitrocellulose membranes using the Trans-Blot Cell (Bio-Rad) according to the instruction of the manufacturer. After blocking in 5% low-fat dry milk and 2% BSA dissolved in TBST (Tris-buffered saline-Tween 20, pH 7.5) for 1h at room temperature, membranes were probed with IVIG (1:500) or with IVIG depleted of S . aureus specific IgGs (dSaIVIG) using an equal antibody concentration, overnight at 4°C. Membranes were washed in TBST and incubated with anti-human IgG peroxidase conjugate (1:2500) for specific detection of immune complexes.
  • TBST Tris-buffered saline-Tween 20, pH 7.5
  • reaction products were cloned into pENTR/D-TOPO and transformed into E . coli TOP10 (Invitrogen).
  • E . coli TOP10 Invitrogen
  • By LR recombination the genes of interest were transferred from entry clone into pDEST15 destination vector, in order to generate a vector coding for the N-terminal GST-fusion protein.
  • E. coli BL21 harbouring the recombinant plasmids were grown in LB medium containing ampicillin at 30°C until the cultures reached an OD 600 of ⁇ 0.6. The protein expression was induced with 0.5 mM IPTG for 4 h at 27°C.
  • Bacterial cells were harvested by centrifugation, washed with 1xPBS and resuspended in 1xPBS containing protease inhibitors and lysed mechanically using the French Press (Thermo Scientific, Waltham, US). The bacterial debris was removed by subsequent centrifugation at 17,000 x g.
  • the expression of soluble protein was assessed by SDS-PAGE.
  • the recombinant proteins were purified by affinity chromatography using glutathione sepharose prepacked GSTrap FF columns on the ⁇ KTApurifier liquid chromatography system (GE Healthcare) according to the manufacturers instructions.
  • Affinity absorption of specific IgGs from IVIG In order to enrich specific IgGs, 5-10 mg purified recombinant protein (rEno, rOxo, rhp2160) were covalently linked to the NHS-activated Sepharose according to the manufacturers instructions (GE Healthcare). The absorption of IgGs was performed ON at 4°C by slow recirculation of IVIG previously transferred into PBS buffer (pH 7.3) using the HiPrep 26/10 Desalting column (GE Healthcare).
  • IgGs were eluted from the column using 0.1 M Glycine-HCL, pH 2.7 on the ⁇ KTApurifier liquid chromatography system. The pH of the eluted fractions was neutralised by collecting them into a sufficient amount of 1M Tris-HCL, pH 9. IgG containing fractions were pooled and after buffer exchange into 1 x PBS, pH 7.3 concentrated using Centricon Plus-70 centrifugal filter units with a 30.000 MWCO membrane (Millipore, Schwalbach, Germany).
  • PMNs Human polymorphonuclear cells
  • GFP-expressing S . aureus ATCC 29213 from ON culture was inoculated into 25 ml of LB broth and grown at 37°C to an OD 600 of 0.3. Bacteria were harvested, washed and adjusted to 1x10 9 CFU/ml.
  • IVIG, dSaIVIG or enriched specific IgGs were applied in a concentration of 500 ⁇ g/ml, which corresponds to the average IgG concentration present in 2.5% human serum.
  • IgGs, 2.5 x 10 6 human PMNs and bacteria in a MOI (multiplicity of infection) of 10 were incubated for 60 s at 37°C with slow rotation, pelleted by centrifugation for 60 s at 400 x g at 37°C and further incubated for 60 s at 37°C, in order to synchronise phagocytosis. Pellets were resuspended and the phagocytosis was stopped by differential centrifugation for 5 min at 150 x g at 4°C. Immediately after centrifugation (t3) an aliquot was removed and stored in a 1:5 dilution in 0.5% BSA/PBS, pH7.3 at 4°C until FACS analysis was performed.
  • MOI multiplicity of infection
  • mice Female C57/ BL6 mice (6-8 weeks) were purchased from Charles River Laboratories (Sulzfeld, Germany). Groups of 7 mice were administered intraperitoneally (i.p.) with an 1:1 emulsion of 100 ⁇ g recombinant protein (rEno, rOxo or rhp2160) and complete Freund's Adjuvant (Sigma) in a total volume of 200 ⁇ l on day 0, followed by subcutaneous (s.c.) administration of three booster doses using an emulsion of 50 ⁇ g antigen and incomplete Freund's Adjuvant (1:1) on day 14, day 28 and day 42. Mice immunised with an emulsion of BSA and adjuvant served as controls. Blood samples were taken from each mouse one week after the last booster injection, in order to determine the antibody titer.
  • rEno, rOxo or rhp2160 complete Freund's Adjuvant
  • Enzyme-linked immunoabsorbent assay was used to determine levels of antibodies directed against Eno, Oxo and hp2160 protein in sera of immunised mice.
  • 96-well polystyrene maxisorb plates (Nunc, Wiesbaden, Germany) were coated overnight at 4°C with 5 mg/ml of the recombinant antigen (rEno, rOxo, rhp2160), BSA or GST in PBS, pH 7.3.
  • the wells were washed three times with PBS containing 0.05% Tween 20 (PBST) and blocked using Starting Block T20/PBS (Pierce) for 30 min at RT.
  • mice sepsis model The infection of mice was performed using the bioluminescent S. aureus Xen29 strain ( Francis K. P. et al., Infect. Immun., 68(6):3594-600 (2000 ); Kadurugamuwa J. L. et al., Infect. Immun., 71(2):882-90 (2003 )). Prior to infection the mice were shaved ventrally to enable light detection. The animals were challenged intravenously (i.v.) with an inoculum of 1 x 108 CFU S . aureus Xen29 two weeks after the last booster injection. Bacterial inoculum was assessed by plating a serial dilution on MH agar plates and counting the CFU.
  • mice were monitored daily over a time course of 3 days post infection in an anaesthetised state (isofluoran-oxygen gas mixture) using the IVIS imaging system (Xenogen Corp.). Mice were imaged in ventral position for 5 min exposure. An untreated control mouse was included in every image to detect the background photon emission. The infection rate was displayed in a pseudocolour scale representing the number of photons per second emitted from the mice. Highly intensive bioluminescence signals were displayed as red and low intensity signals as blue. The light intensity within defined regions of interest (ROIs) was quantified using the LivingImage software (Xenogen Corp.). Bioluminescent signals were quantified by setting the ROIs over the ventral side of the animal body. Extremities, tail and head were excluded from the analysis.
  • ROIs defined regions of interest
  • IVIG contains opsonising antibodies to S.aureus: To determine whether commercial IVIG preparations are suitable antibody sources for the identification of immunoreactive antigens, an IVIG preparation (Octagam ® ) was tested in vitro for opsonising antibodies to S . aureus. The presence of opsonising antibodies was investigated in a PMNs-mediated opsonophagocytosis assay. The efficacy of complement-independent IVIG-mediated phagocytosis was compared to phagocytosis induced by 2.5% heat-inactivated human serum (HIserum).
  • HIserum heat-inactivated human serum
  • Detection and identification of immunogenic staphylococcal surface proteins by 2-DE analysis In order to identify antigenic proteins, recognised by IgGs present in IVIG, cell wall associated proteins from S . aureus (clinical isolate ATCC 29213) were separated by 2-DE electrophoresis, followed by Western blot analysis using IVIG and dSaIVIG. To achieve high-quality spot resolution and to ensure adequate spot matching and identification, proteins were separated in two different pH ranges, pH 3-10 ( Fig. 2A ) and pH 4-7 ( Fig. 2B ), in series of three gels in parallel for each pH range. One of the gels was used for immunoblotting, probing the same blot twice, first with dSaIVIG ( Fig.
  • IVIG and dSaIVIG produced reproducibly distinct immunoblot profiles of 2-DE separated S. aureus surface proteins.
  • the depletion of S. aureus-specific, opsonising IgGs by absorption of IVIG with S . aureus resulted in a considerably lower number of spots compared to immunoblots treated with IVIG ( Fig. 2 , top and middle).
  • proteins solely recognised by complete, but not with dSaIVIG may serve as vaccine candidates.
  • proteinspots strongly reacting with both, IVIG and dSaIVIG were supposed to be recognised by IgGs, that lack specificity for S.
  • aureus antigens were therefore excluded from further investigation.
  • the two other gels were stained either with silver ( Fig. 2 , bottom) or coomassie (not shown). Spots of interest were cut from the coomassie stained gel and used for MALDI-TOF analysis. Eventually, about 40 proteins were identified using SUPRA (Table 1).
  • Eno Enolase
  • Oxo oxoacyl-reductase
  • hp2160 hypothetical protein 2160
  • Opsonic effect of anti- Eno, -Oxo and -hp2160 antibodies The opsonic activity of the affinity purified antibodies against rEno, rOxo and rhp2160 (anti-Eno, -Oxo and -hp2160) was analysed in a human PMNs-mediated opsonophagocytosis assay. The uptake of GFP-expressing S . aureus by human PMNs in presence of specific antibodies was monitored by flow cytometry. The opsonophagocytic activity mediated by the individual antibodies was compared to opsonophagocytic activity induced by IVIG and HIserum. As shown in Fig.
  • Immunisation with rEno, rOxo and rhp2160 induces significant levels of specific anti-S.aureus antibodies: Encouraged by the fact that anti-Eno, Oxo and hp2160 were able to induce opsonophagocytic killing of S . aureus by human PMNs in vitro, we used the recombinant proteins to induce a protective immune response to S . aureus infection in mice. Groups of 7 mice were immunised either with rEno, rOxo or rhp2160 and BSA as control. One week after the third administration of the booster injection the level of specific antibodies in serum was determined using ELISA.
  • mice protected against S . aureus infection: To determine whether the immune response elicited by rEno, rOxo and rhp2160 was able to protect mice against S . aureus, immunised mice were challenged intravenously (i.v.) with the virulent, bioluminescent S . aureus Xen 29 strain with an inoculum of 10 8 CFU. Mice were monitored by IVIS ( in vivo imaging system ) to follow the spreading of bacteria from day 1 to day 3 of infection.
  • IVIS in vivo imaging system
  • Fig. 7A The in vivo bioluminescence images of the ventral side of an uninfected control, mock-immunised and recombinant protein-immunised mice are shown in Fig. 7A . Whereas a progressive increase of bioluminescence was observed in mice immunised with BSA, no significant increase of bioluminescence was detected in mice treated with rEno, rOxo or rhp2160. Quantitative analysis of emitted photons per second counted within the "legion of interest" (ROI) for each imaged mouse is shown in Fig. 7B . Nearly constant bioluminescence values were observed in vaccinated mice over the course of infection, whereas a significant proliferation of bacteria, resulting in up to 10-fold increase of the bioluminescent signals, was measured in the group of mock-immunised mice.
  • ROI legion of interest
  • CFUs of S . aureus in liver, kidneys, heart, lung and spleen were determined.
  • Vaccination with rEno, rOxo or rhp2160 resulted in remarkably lower S . aureus densities in all target tissues compared to the bacterial load in animals receiving BSA ( Fig. 7C ). The most obvious difference was observed in liver and heart tissue. In the liver the hp2160 immunised group revealed a 100-fold lower colonisation rate compared to the controls, followed by Oxo with a 10-fold lower bacterial load and finally Eno with 5-fold less bacteria. The in vivo data demonstrate that the immunisation with all three candidates (Eno, Oxo and hp2160) induces a protective immune response, which reduces an uncontrolled spread of S . aureus infection in mice.
  • Table 1 Cell wall-associated immunogenic antigens from S . aureus ATCC 29213 identified by MALDI-TOF SEQ ID NO GenBank Acc. No. Spot ID Putative identification p I a MW b (kDa) MAS COT c Tot. score Seq.
  • IgGs exhibit a bacteriostatic effect on S . aureus growth in vitro: In order to analyse whether S . aureus specific IgGs could influence bacterial growth CFU numbers were compared over a period of three hours. As shown in figure 8 IVIG exhibits a bacteriostatic effect on S . aureus growth during the first two hours post inoculation. A comparable effect was observed when IVIG preabsorbed with E. coli (dEcIVIG) was used, whereas IVIG depleted of specific IgGs(dSaIVIG) did not influence the growth of S , aureus. These data indicate that the bacteriostatic effect is mediated exclusively by specific IgGs.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (9)

  1. Composition pharmaceutique ou médicament comprenant au moins une protéine de Staphylococcus aureus associée à la paroi cellulaire qui est la triose-phosphate-isomérase de SEQ ID N° : 38, ou un fragment ou dérivé de celle-ci entraînant une réponse immunitaire qui induit l'activité opsonophagocytaire des neutrophiles humains pour le S. aureus.
  2. Composition pharmaceutique ou médicament selon la revendication 1, dans lequel la protéine associée à la paroi cellulaire
    (i) est dérivée de la souche de S. aureus ATCC 29213 ; et/ou
    (ii) ne réagit qu'avec une préparation à base d'immunoglobuline intraveineuse (IVIG) mais pas avec une préparation IVIG appauvrie en anticorps opsonisants spécifiques de S. aureus.
  3. Composition pharmaceutique ou médicament selon la revendication 1 ou 2, la composition ou le médicament comprenant en outre une ou plusieurs protéines associées à la paroi cellulaire du S. aureus sélectionnées parmi l'énolase (Eno) de SEQ ID N° : 2, la 3-oxoacyl-réductase (Oxo) de SEQ ID N° : 3, la protéine de type NADH-déshydrogénase de SEQ ID N° : 4, la protéine de type protéine de liaison anionique de SEQ ID N° : 5, la peptidoglycane hydrolase de SEQ ID N° : 6, la protéine hypothétique conservée de SEQ ID N° : 7, l'antigène A immunodominant de SEQ ID N° : 8, l'aldéhyde déshydrogénase de SEQ ID N° : 9, la bêta-hémolysine tronquée de SEQ ID N° : 10, l'homologue du précurseur d'antigène sécrétoire SsaA de SEQ ID N° : 11, la protéine ribosomique 50S L13 de SEQ ID N° : 12, la protéine hypothétique conservée de SEQ ID N° : 13, le facteur d'élongation de traduction TU de SEQ ID N° : 14, l'autolysine de SEQ ID N° : 15, la protéine hypothétique de SEQ ID N° : 16, la protoporphyrinogène oxydase de SEQ ID N° : 17, la protéine de type précurseur de toxine synergohyménotrope de SEQ ID N° : 18, la sous-unité A de la glutamyl-t-RNAGIn-amidotransférase de SEQ ID N° : 19, l'homologue de l'aminotransférase NifS de SEQ ID N° : 20, le facteur d'élongation de traduction TU de SEQ ID N° : 21, la protéine hypothétique de SEQ ID N° : 22, l'antigène A immunodominant de SEQ ID N° : 23, la chaîne bêta d'ATP synthase de SEQ ID N° : 24, l'alanine déshydrogénase de SEQ ID N° : 25, la phosphopentomutase de SEQ ID N° : 26, la glutamate déshydrogénase NAD-spécifique de SEQ ID N° : 27, la protéine de type précurseur d'autolysine de SEQ ID N° : 28, l'homologue de la chorismate mutase de SEQ ID N° : 29, la protéine de type précurseur de SceD de SEQ ID N° : 30, la protéine hypothétique de SEQ ID N° : 31, l'uridylate kinase de SEQ ID N° : 32, le répresseur de transcription pléiotrope codY de SEQ ID N° : 33, l'entérotoxine SEM de SEQ ID N° : 34, la protéine de transport du ferrochrome se liant à l'ATP de SEQ ID N° : 35, la protéine hypothétique conservée de SEQ ID N° : 36, la protéine ribosomique 50S L25 de SEQ ID N° : 37, la Xaa-Pro dipeptidase de SEQ ID N° : 39 et les fragments et dérivés de ceux-ci.
  4. Composition pharmaceutique ou médicament selon l'une quelconque des revendications 1 à 3, dans lequel les fragments comprennent au moins 10 acides aminés.
  5. Composition pharmaceutique ou médicament selon l'une quelconque des revendications 1 à 4, dans lequel les dérivés englobent les modifications de groupes fonctionnels, la liaison de groupes fonctionnels, la liaison à au moins un domaine protéique fonctionnel supplémentaire et la liaison à d'autres molécules biologiquement actives.
  6. Composition pharmaceutique ou médicament selon l'une quelconque des revendications 1 à 5, qui est un vaccin de protection contre le Staphylococcus aureus.
  7. Utilisation de la protéine de S. aureus associée à la paroi cellulaire ayant SEQ ID N° : 38, ou d'un fragment ou dérivé de celle-ci pour la préparation d'un vaccin de protection contre le Staphylococcus aureus.
  8. Composition pharmaceutique ou médicament comprenant au moins un anticorps dirigé contre la protéine de Staphylococcus aureus associée à la paroi cellulaire ayant SEQ ID N° : 38, ou un fragment ou dérivé de celle-ci.
  9. Utilisation d'un anticorps dirigé contre la protéine de Staphylococcus aureus associée à la paroi cellulaire ayant SEQ ID N° : 38, ou d'un fragment ou dérivé de celle-ci pour la préparation d'un médicament destiné au traitement d'une infection par le Staphylococcus aureus chez un humain ou un animal.
EP11169342.0A 2007-05-04 2007-05-04 Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire Active EP2374466B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11169342.0A EP2374466B1 (fr) 2007-05-04 2007-05-04 Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11169342.0A EP2374466B1 (fr) 2007-05-04 2007-05-04 Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire
EP07107512A EP1987836B1 (fr) 2007-05-04 2007-05-04 Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP07107512.1 Division 2007-05-04

Publications (2)

Publication Number Publication Date
EP2374466A1 EP2374466A1 (fr) 2011-10-12
EP2374466B1 true EP2374466B1 (fr) 2013-08-28

Family

ID=38895836

Family Applications (3)

Application Number Title Priority Date Filing Date
EP11169342.0A Active EP2374466B1 (fr) 2007-05-04 2007-05-04 Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire
EP07107512A Active EP1987836B1 (fr) 2007-05-04 2007-05-04 Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire
EP11169347.9A Active EP2374467B1 (fr) 2007-05-04 2007-05-04 Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP07107512A Active EP1987836B1 (fr) 2007-05-04 2007-05-04 Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire
EP11169347.9A Active EP2374467B1 (fr) 2007-05-04 2007-05-04 Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire

Country Status (3)

Country Link
US (1) US20080299127A1 (fr)
EP (3) EP2374466B1 (fr)
AT (1) ATE537839T1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2638058B1 (fr) * 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptidiques vaccins conjugues contre staphylococcus aureus
US9527892B2 (en) 2011-10-31 2016-12-27 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2451 protein
WO2014011645A1 (fr) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Vaccin protecteur à base de protéine sa2493 de staphylococcus aureus
EP3363459A1 (fr) 2017-02-17 2018-08-22 Alexander Klimka Polypeptides épitopes de s. aureus et anticorps anticorps monoclonaux respectifs pour le traitement d'infections et le diagnostic immunitaire
CN114088946B (zh) * 2021-07-02 2024-03-29 中国科学技术大学 转录调控因子WalR和MgrA的亚硝基化修饰在治疗金黄色葡萄球菌感染中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CA2808598A1 (fr) * 2001-08-02 2003-02-13 University Of Sheffield Polypeptides antigenes
CA2532370A1 (fr) * 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides pour l'induction d'une reponse immunitaire de protection contre le staphylococcus aureus
MX2007003402A (es) * 2004-09-22 2007-05-10 Glaxosmithkline Biolog Sa Composicion inmunogena para su uso en vacunacion contra estafilococos.

Also Published As

Publication number Publication date
EP2374467B1 (fr) 2013-08-28
ATE537839T1 (de) 2012-01-15
US20080299127A1 (en) 2008-12-04
EP1987836B1 (fr) 2011-12-21
EP2374467A1 (fr) 2011-10-12
EP2374466A1 (fr) 2011-10-12
EP1987836A1 (fr) 2008-11-05

Similar Documents

Publication Publication Date Title
US10682404B2 (en) Targets of Acinetobacter baumannii
EP2374466B1 (fr) Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire
AU2007232894B2 (en) Pseudomonas aeruginosa outer membrane protein PA0427
US20100330100A1 (en) Pseudomonas aeruginosa-outer membrane protein pa4710
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
AU2006307018B2 (en) Outer coat protein PA5158 of Pseudomonas aeruginosa
US20130243779A1 (en) Peptides protective against e. faecalis, methods and uses relating thereto
US20130309264A1 (en) Novel antigen of enterococcal pathogens and use therof as vaccine component for therapy and/or prophylaxis
WO2019113599A1 (fr) Nanocorps neutralisant des toxines bactériennes et leurs procédés de fabrication et d'utilisation
Mirali et al. A two-protein cocktail elicits a protective immune response against Acinetobacter baumannii in a murine infection model
Hou et al. Mechanism of Action for an All-in-One Monoclonal Antibody Against Staphylococcus aureus Infection
EP2915543B1 (fr) Polypeptides dérivés de enterococcus et leur utilisation pour la vaccination et la génération d'anticorps thérapeutiques
Tosetti Characterisation of new potential vaccine candidates against infections caused by Staphylococcus aureus
Hira et al. Vaccination with SesC decreases Staphylococus epidermidis biofilm formation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1987836

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KROENKE, MARTIN, PROF. DR.

Inventor name: GLOWALLA, EVA

Inventor name: KRUT, OLEG

Inventor name: TOSETTI, BETTINA

17P Request for examination filed

Effective date: 20120405

17Q First examination report despatched

Effective date: 20120628

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1987836

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 628896

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007032603

Country of ref document: DE

Effective date: 20131024

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 628896

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130828

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131228

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131230

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130619

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131129

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007032603

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140530

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007032603

Country of ref document: DE

Effective date: 20140530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140504

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140531

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070504

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230517

Year of fee payment: 17

Ref country code: DE

Payment date: 20230525

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230522

Year of fee payment: 17